Extensive research indicates that agonists of CB1 and CB2 receptors can exert anti-inflammatory, analgesic, microcirculation-improving, anti-cancer activities and treat neurodegenerative diseases (Mackie, 2006; Riether, 2012; Morales et al., 2016). The gene discussed is CNR1; the disease is neurodegenerative disease.